Aventis Pharmaceuticals Inc.

Rhone-poulenc Rorer Pharmaceuticals Inc.

Other

Rorer Pharmaceutical Corporation

Charles J Gardner

Hazel Joan Hunt

Timothy A Gillespy

Michael L Edwards

Andrew David Morley

Herve Bouchard

Bruce F Molino

Scott I Klein

Tahir Nadeem Majid

Paul Joseph Cox

Mark Czekaj

Brian L Pedgrift

Shelley Amendola

Christopher D Edlin

Stephanie Deprets

Frank Halley

Didier Babin

Dominique Damour

John Charles Reader

Conception Nemecek

Francois Clerc

Michael Cherry

Jeffrey C Pelletier

Chantal Carrez

Dorothea Kominos

Nawaz Mohammed Khan

Justine Yeun Quai Lai

Laurence Gauzy

Olivier Houille

Alain Le-Brun

Lloyd J Payne

Daniel N A Bezard

Hazel Joan Dyke

Michael R Becker

Elsa Amandine Dechaux

Sungtaek Lim

Keith John Harris

Bin Cao

Jeffrey M Dener

David Stefany

Ray Boffey

Joacy C Aguiar

Stephanie D Deprets

Ray Argenta Discovery Ltd Boffey

It is important to be able to drag a large animal through the woods after it has been killed. This device will allow the hunter to lift the animal's head above the ground as well as the legs in a pair of openings that will elevate the head of the animal off the ground surface so that the animal may be dragged. The handle may also telescope and will allow more than one hunter to grab the device in order to safely pull the animal through the woods.

Game hauler

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Benzimidazoles

The present invention is directed to a compound of Formula (I) wherein Cy, Cy, L, L, and Rare as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

The invention is directed to physiologically active compounds of the general formula (Ix)and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-�N-�N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl!-(L)-aspartyl!-(L)-.beta. -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.

Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides

This invention relates to novel peptide and pseudopeptide derivatives and analogs of aspartic acid which are useful as inhibitors of platelet aggregation and thrombus formation in mammalian blood, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.

Antithrombotic peptides and pseudopeptides

Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof containing certain amino acids and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.

Anti-thrombotic peptides and pseudopeptides

Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.

Growing community of inventors

Royersford, NJ, United States of America

Charles J Gardner